메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

D3 Bio Secures $108 Million in Series B Financing to Advance G…

SHANGHAI, Dec. 10, 2025 -- D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round. The funding round was backed by a distinguished group of investors, including IDG Capital and SongQing Capital. Existing investors — WuXi AppTec's Corporate Venture Fund, Temasek, HSG, MPCi, and Medicxi — also contributed to the round. The robust involvement from both new and current investors highlights widespread confidence in D3 Bio's in
- 김갑성 기자
- 2025-12-10 09:30
Innovent Announces First Participant Dosed in a Phase 1 Cli…

[ 메디채널 김갑성 기자 ] SAN FRANCISCO and SUZHOU, China, Dec. 10, 2025 -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major disease areas, announced that the first participant has been successfully dosed in a Phase 1 clinical trial of IBI3011, an anti-human Interleukin 1 receptor accessory protein (IL-1RAP) monoclonal antibody developed by Innovent. This study is a single ascending
- 김갑성 기자
- 2025-12-10 08:26
Lee's Pharmaceutical Holdings Limited Acquires Staccato®…

Acquisition of Staccato® One Breath Technology®, a proprietary platform technology with broad therapeutic potential Synergistic and complementary to Lee's Pharm's existing products pipeline, and Acquisition of rights as licensor and manufacturer of Staccato® alprazolam under a global partnership with UCB HONG KONG, Dec. 10, 2025 -- Nova Pneuma Inc. ("NPI"), the Delaware incorporated and wholly owned subsidiary of Lee's Pharmaceutical Holdings Limited (0950.HK) ("Lee's Pharm" or the "Company"), announced today the assets acquisi
- 김갑성 기자
- 2025-12-10 08:00
PhyxUp Health Leads Innovation in US Rehabilitation Market wi…

SAN FRANCISCO, Dec. 10, 2025 -- PhyxUp Health, an AI-driven Remote Therapeutic Monitoring (RTM) platform founded by a former physical therapist and Harvard graduate, is transforming how rehabilitation clinics operate throughout the United States. Built as a next-generation patient management and engagement solution, PhyxUp enables clinics to remotely monitor patient progress, increase therapy adherence, and streamline communication beyond the clinic walls. The platform incorporates automated documentation and integrated RTM billing, ensuring clean reimbursement workflows that help outpatient
- 김갑성 기자
- 2025-12-10 00:00
BestQool Launches Christmas Campaign Crossing Into 2026…

NEW YORK, Dec. 9, 2025 -- BestQool is now giving a holiday offer to help people smoothly move into 2026 as the year comes to an end and the holidays approach. From December 10, 2025, to January 4, 2026, customers can get 15% off all BestQool light therapy products on the BestQool official website. Also, from December 24, 2025, to January 6, 2026, customers who want red light devices that look like belts or yoga mats can get up to 23% off Redot series products when they buy them from the BestQool Amazon store. This Christmas, give the gift of health. The holidays are fun, but th
- 김갑성 기자
- 2025-12-09 23:56
메나리니 그룹, 2025 샌안토니오 유방암 심포지엄에서 엘라세스트란트(ORSERDU)®의 E…

또한, 광범위한 엘라세스트란트 임상 개발 프로그램 업데이트는 전이성 유방암과 초기 단계 유방암 모두에서 병용 요법의 기반이 되는 내분비 치료로서의 잠재력을 강화한다. 이탈리아 피렌체 및 뉴욕, 2025년 12월 9일 -- 선도적인 글로벌 제약 및 진단 기업인 메나리니 그룹(Menarini Group, 이하 '메나리니')과 스템라인 테라퓨틱스(Stemline Therapeutics, Inc. , 이하 '스템라인')가 에스트로겐 수용체 양성(ER+), HER2 음성(HER2-) 국소 진행성 또는 전이성 유방암(mBC) 환자를 대상으로 한 2상 ELEVATE 연구에서 두 가지 병용 치료군의 의미 있는 무진행 생존기간 중앙값(mPFS) 최신 결과를 발표한다. 스템라인 테라퓨틱스는 메나리니 그룹의 전액 출자 자회사로 암 환자에게 혁신적인 종양 치료를 제공하는 데 주력한다. ELEVATE 연구는 ER+/HER2- mBC에서 관찰되는 다양한 내성 기전을 극복해 환자 치료 성과를 향상시키는 것을 목표로, 경구-경구 병용 요법의 안전성과 유효성을 평가하도록 설계된 연구다. 관련 데이터는 12월 9~12일 열리는 2025년 샌안토니오 유방
- 김갑성 기자
- 2025-12-09 22:49
Neurophet Introduced Use Cases of Its AI-based Brain Imag…

Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse effects related to Alzheimer's disease treatments Highlighted clinical value of Neurophet AQUA AD…To accelerate efforts across healthcare institutions in Southeast Asia SEOUL, South Korea, Dec. 9, 2025 -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 9th that it participated in a symposium held on the 28th of last month (local time). The event was h
- 김갑성 기자
- 2025-12-09 22:00
Medit Launches AuraVue: A Unified 3D Intraoral Scan and X-…

NEWPORT BEACH, Calif., Dec. 9, 2025 -- Medit, a global leader in 3D intraoral scanning and digital dentistry solutions, today announced the launch of AuraVue, a next-generation visualization and consultation platform that integrates Overjet's AI technology to deliver real-time diagnostic insights and clearer patient communication. With AuraVue, clinicians can now view 3D intraoral scans and X-rays side by side in one interactive workspace. By combining Medit's 3D imaging with Overjet's AI-powered radiographic analysis, AuraVue transforms diagnostic data into clear, visu
- 김갑성 기자
- 2025-12-09 21:30
AI CAD-OCI Integration Underway: ALL CONEC Begins Validation…

SEOUL, South Korea, Dec. 9, 2025 -- ALL CONEC has been chosen as a participant in the Dream Venture Star 11 Oracle × Uclick Program and will begin validating a unified data workflow for digital prosthetic production. The initiative focuses on integrating design, fabrication, and inspection data—generated from ALL CONEC's AI CAD, ERP, 3D viewer, and IoT 3D printer solutions—into the Oracle Cloud Infrastructure (OCI) environment. In the current workflow, various data points created across stages of prosthetic production are often managed separately. ALL CONEC aims to store a
- 김갑성 기자
- 2025-12-09 19:55
Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into…

SHANGHAI, Dec. 9, 2025 -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products con
- 김갑성 기자
- 2025-12-09 19:55

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-12-10_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 12월 10일 19시 00분